![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
NORTHERA(TM) Clinical Trial Data Published in Neurology
19 juin 2014 16h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., June 19, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the publication in Neurology of its pivotal, Phase 3 study 301, a multicenter,...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Presents Efficacy and Safety Data for NORTHERA at International Congress of Parkinson's Disease and Movement Disorders
12 juin 2014 07h30 HE
|
Chelsea Therapeutics
-First Presentation of Integrated Data Analyses From Two Pivotal Trials
-Data Shows Statistically Significant Improvement in Symptoms of NOH vs. Placebo
CHARLOTTE, N.C. and STOCKHOLM, Sweden,...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Announces the Expiration of the Hart-Scott-Rodino Waiting Period in Relation to the Proposed Acquisition of Chelsea Therapeutics by Lundbeck
06 juin 2014 07h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., June 6, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics to Host Conference Call to Discuss Acquisition by Lundbeck
08 mai 2014 07h58 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Chelsea) (Nasdaq:CHTP), a biopharmaceutical development company, has entered into a definitive agreement to...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Lundbeck to Acquire Chelsea Therapeutics
08 mai 2014 07h54 HE
|
Chelsea Therapeutics
By acquiring Chelsea Therapeutics, Lundbeck gains the rights to Chelsea Therapeutics' recently FDA-approved product, NORTHERATM (droxidopa), which is expected to be launched later in 2014...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Reports Fourth Quarter and Full-Year 2013 Results
11 mars 2014 16h25 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., March 11, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31,...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
28 févr. 2014 07h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 28, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERATM...
![Chelsea Therapeutics Logo](/news-release/logo/213571/0/213571.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A25&size=2)
Chelsea Therapeutics Issues Statement Regarding Postponement of NORTHERA(TM) (Droxidopa) NDA PDUFA Action Date Due to Severe Weather
14 févr. 2014 18h55 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today issued the following statement regarding the U.S. Food and Drug Administration (FDA)...
![Keith W. Schmidt](http://www.globenewswire.com/fr/Attachment/LogoDisplay/282006?filename=282006.jpg&size=2)
Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer
30 janv. 2014 07h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Keith W. Schmidt has been named Chief Commercial Officer, effective...
![Joseph G. Oliveto](http://www.globenewswire.com/fr/Attachment/LogoDisplay/281592?filename=281592.jpg&size=2)
Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director
27 janv. 2014 07h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Joseph G. Oliveto has been named President and Chief Executive Officer...